News
EQS-News: Burcon NutraScience Corp.: Burcon Adds Climate Tech Specialist, Aaron T. Ratner to the Board
EQS-News: Burcon NutraScience Corp.: Burcon Announces Results of Shareholder Meeting
EQS-News: Burcon JV, Merit Functional Foods and Canadian Partners to Develop New Line of Plant-based Seafood Alternatives
EQS-News: Burcon to Present at the Canaccord Genuity AgriFood Tech Innovation Virtual Forum
IMV Inc. Announces Third Quarter 2022 Financial and Operational Results
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat
EQS-News: Burcon Reports Fiscal 2023 Second Quarter Results
IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today
EQS-News: Burcon NutraScience Corp.: Burcon Appoints Specialty Protein Executive Kip Underwood as Chief Executive Officer
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three months ended September 30, 2022. Amounts, unless specified otherwise, are
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third quarter 2022 on Thursday, November 3, 2022
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today
EQS-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2023 Second Quarter Conference Call to be Held on November 7, 2022
EQS-News: Burcon NutraScience Corp.: Burcon Announces Annual General Meeting Date
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that
IMV Provides an Update on The VITALIZE Trial
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today
EQS-News: Burcon NutraScience Corp.: Burcon Announces Breakthrough in Sunflower Protein Development
EQS-News: Burcon NutraScience Corp.: Burcon Provides Update on JV, Merit Functional Foods
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced
IMV Inc. Announces Strategic Reorganization
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat
DGAP-News: Burcon NutraScience Corp.: Burcon Issues Shareholder Letter
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Delisting from Nasdaq Capital Market
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Auditor Resignation and AGM Postponement
IMV Inc. to Present at Two Investor Conferences in September
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today